A phase I/II trial of a candidate vaccine to prevent HIV infection was carried out in Bangkok, Thailand, testing AIDSVAX B/E (VaxGen, Inc., Brisbane, CA), a bivalent subunit vaccine prepared by combining recombinant gp120 from a subtype B virus (HIV-1MN) with gp120 from a subtype E virus (HIV-1A244) in alum adjuvant. The studies provide human data on the immunogenicity of various dose combination of non-subtype B vaccine antigens. The results suggest that AIDSVAX B/E is safe and immunogenic in humans. The optimal dose for humans in developing countries was 300 microg of each antigen (B and E). Clade E responses were measurably increased by immunizing with gp120 B/E over B alone. Using the B/E combination did not interfere with the response to either clade. Antibodies to AIDSVAX B/E were able to bind to oligomeric gp120 on the surface of cells infected with primary isolates of HIV-1.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1097/01.qai.0000136091.72955.4b | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Non-HIV Vaccine-Induced Immune Responses as Potential Baseline Immunogenicity Predictors of ALVAC-HIV and AIDSVAX B/E-Induced Immune Responses.
Viruses
August 2024
Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Center, Seattle, WA 98109, USA.
Identifying correlations between immune responses elicited via HIV and non-HIV vaccines could aid the search for correlates of HIV protection and increase statistical power in HIV vaccine-efficacy trial designs. An exploratory objective of the HVTN 097 phase 1b trial was to assess whether immune responses [focusing on those supported as correlates of risk (CoR) of HIV acquisition] induced via the RV144 pox-prime HIV vaccine regimen correlated with those induced via tetanus toxoid (TT) and/or hepatitis B virus (HBV) vaccines. We measured TT-specific and HBV-specific IgG-binding antibody responses and TT-specific and HBV-specific CD4+ T-cell responses at multiple time points in HVTN 097 participants, and we assessed their correlations at peak time points with HIV vaccine (ALVAC-HIV and AIDSVAX B/E)-induced responses.
View Article and Find Full Text PDFSWIFT clustering analysis of intracellular cytokine staining flow cytometry data of the HVTN 105 vaccine trial reveals high frequencies of HIV-specific CD4+ T cell responses and associations with humoral responses.
Front Immunol
June 2024
Department of Microbiology and Immunology, University of Rochester Medical Center, Rochester, NY, United States.
Introduction: The HVTN 105 vaccine clinical trial tested four combinations of two immunogens - the DNA vaccine DNA-HIV-PT123, and the protein vaccine AIDSVAX B/E. All combinations induced substantial antibody and CD4+ T cell responses in many participants. We have now re-examined the intracellular cytokine staining flow cytometry data using the high-resolution SWIFT clustering algorithm, which is very effective for enumerating rare populations such as antigen-responsive T cells, and also determined correlations between the antibody and T cell responses.
View Article and Find Full Text PDFViral vector delivered immunogen focuses HIV-1 antibody specificity and increases durability of the circulating antibody recall response.
PLoS Pathog
May 2023
Center for Human Systems Immunology, Duke University School of Medicine, Durham, North Carolina, United States of America.
Article Synopsis
- The RV144 HIV-1 vaccine gave a 31% efficacy after three years but showed a decline in immune protection; new strategies for enhancing immunity are needed.
- The RV305 trial tested booster shots on RV144 participants years later and found improved immune responses, especially with the ALVAC vaccine boost.
- The study revealed that while overall antibody levels increased, certain antibodies linked to higher HIV-1 risk also rose, highlighting the need for careful evaluation of booster effects on antibody quality.
ALVAC-HIV and AIDSVAX B/E vaccination induce improved immune responses compared with AIDSVAX B/E vaccination alone.
JCI Insight
May 2023
The US Military HIV Research Program, Walter Reed Army Institute of Research, Silver Spring, Maryland, USA.
The RV144 phase III vaccine trial demonstrated that ALVAC-HIV and AIDSVAX B/E administration over 6 months resulted in 31% efficacy in preventing HIV acquisition, while administration of AIDSVAX B/E alone in both VAX003 and VAX004 studies failed to show efficacy. In this study, we aimed to understand the impact of ALVAC-HIV on the development of cellular, humoral, and functional immune responses compared to the administration of AIDSVAX B/E alone. ALVAC-HIV in combination with 3 doses of AIDSVAX B/E significantly increased CD4+ HIV-specific T cell responses, polyfunctionality, and proliferation compared with 3 doses of AIDSVAX B/E alone.
View Article and Find Full Text PDFAIDSVAX protein boost improves breadth and magnitude of vaccine-induced HIV-1 envelope-specific responses after a 7-year rest period.
Vaccine
July 2021
Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA. Electronic address:
Article Synopsis
- The HVTN 114 vaccine trial aimed to enhance durable humoral immunity against HIV-1 by testing different vaccination boosters after a 7-year gap for participants from previous trials.
- The study involved 27 participants divided into five groups, receiving various combinations of MVA/HIV62B and AIDSVAX B/E for immunization and monitoring their immune responses over 10 months.
- Results showed that all booster regimens were safe, with AIDSVAX significantly increasing binding antibody responses and T-cell responses compared to previous vaccinations in HVTN 205, indicating a promising strategy for future HIV-1 vaccine development.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!